Slayback Pharma

Slayback is founded on the principle of “connecting the dots”. This principle translates into their philosophy of connecting one idea with another. The idea is to conceptualize and develop complex generic and specialty drugs. They focus on products that are challenging and highly complex to develop and/or manufacture. It could be a complex oil-in-water emulsion or a sterile long acting injectable using nano-spheres or sterile suspensions with complex particle physics. They have also worked on complex hormonal products with challenging cross-contamination issues. They aim to optimize the use of technology and potential (generated from a strong experience in this field) to develop a value proposition for their customers. Through this process of drug development, they remotely aim at reducing the cost of therapy by bringing expensive branded drugs within the reach of patients.

Slayback Pharma headquartered in United States, North America, operates in the Pharmaceutical, Manufacturing, Biopharma sector. The company focuses on Pharmaceutical and has secured $2.6B in funding across 24 round(s). With a team of 101-250 employees, Slayback Pharma is actively contributing to advancements in Pharmaceutical. Their latest funding round, Private Equity Round - Slayback Pharma, raised $60.0M. Discover more about their projects, partnerships, and impact on our platform.